• KOLs Community
    • Ischemic
    • Ischemic Stroke
    • Geoffrey Alan Donnan
    • Geoffrey Alan Donnan

      Geoffrey Alan Donnan

      Andrei V. Alexandrov, is Professor and Chairman, Department of Neurology, College of Medicine, University of Tennessee Health Sciences Center, Memphis, TN (ORCID: ...



      KOL Resume for Geoffrey Alan Donnan


      Andrei V. Alexandrov, is Professor and Chairman, Department of Neurology, College of Medicine, University of Tennessee Health Sciences Center, Memphis, TN (ORCID: https://orcid.org/0000-0001-8871-1023).

      The Melbourne Brain Centre, Royal Melbourne Hospital, University of Melbourne, 4/300 Grattan St, 3050, Parkville, VIC, Australia


      Melbourne Brain Centre, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia (G.A.D.)

      CIRCA consortium (E.H.L., G.W.A., M.D., G.D., E.E., R.F., D.W.H., Y-G.H., X.J., E.B.K., S.L., W.L., D.S.L., I.L., E.T.M., M.A.M., M.N., D.R., S.S., J.L.S., F.A.J.L.S., M.S., S.T., F.Z., A.M.B.), Massachusetts General Hospital, Harvard Medical School, Boston.


      Department of Medicine and Radiology, Faculty of Medicine, Dentistry and Health Sciences (H.Z., S.C., D.E., P.M.D., R.J.D., P.J.M., N.Y., B.Y., B.C.V.C., M.W.P., G.A.D., S.M.D.), Austin Health, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Victoria, Australia.

      Melbourne Brain Centre at Royal Melbourne Hospital, University of Melbourne, Parkville, Australia


      The Florey Institute of Neuroscience and Mental Health, Parkville, Australia


      The Florey Institute of Neuroscience and Mental Health, Australia, http://orcid.org/0000-0001-6324-3403, View further author information

      Florey Institute of Neurosciences and Mental Health, Parkville, Vic., Australia



      Geoffrey Alan Donnan: Influence Statistics

      Sample of concepts for which Geoffrey Alan Donnan is among the top experts in the world.
      Concept World rank
      ischemic stroke feasibility #1
      mimics preschool diagnosis #1
      ambulance assistance #1
      relcbf relcbf tmax #1
      initially volume #1
      presence hidden mismatch #1
      bias bench #1
      nurses msus #1
      carotidynia symptom #1
      ambulance practice #1
      subacute imaging #1
      infarct growth tpa #1
      trials neuroprotection #1
      clinical outcome drugs #1
      administration streptokinase #1
      parenchymal haemorrhage #1
      mpn thromboelastography #1
      endovascular symptom onset #1
      activity participation decrease #1
      fu5d #1
      hidden mismatch #1
      thrombolytic evaluation #1
      mobile service conventional #1
      vlcbv stroke thrombolysis #1
      activity participation time #1
      48 hours localization #1
      intracranial vessel occlusion #1
      oral nimodipine placebo #1
      indigenous patients hsvd #1
      stroke comparison #1
      access scus #1
      ambulance stroke patients #1
      18ffmiso binding #1
      maximum dose 90 #1
      dextran embolic signals #1
      mptp mazindol binding #1
      stroke chronic disease #1
      mismatch volume presence #1
      reperfusion activator treatment #1
      contralateral sm1 sma #1
      regulatory issues approval #1
      collateral quality baseline #1
      airmsu #1
      scus 95 #1
      stroke tissue humans #1
      stroke patients ambulance #1
      2 neurologists #1
      imaging thrombolytic #1
      severe arch atheroma #1
      infarct volume 6 #1


      Prominent publications by Geoffrey Alan Donnan

      KOL-Index: 23358

      BACKGROUND: Alteplase is effective for treatment of acute ischaemic stroke but debate continues about its use after longer times since stroke onset, in older patients, and among patients who have had the least or most severe strokes. We assessed the role of these factors in affecting good stroke outcome in patients given alteplase.

      METHODS: We did a pre-specified meta-analysis of individual patient data from 6756 patients in nine randomised trials comparing alteplase with placebo or open ...

      Known for Stroke Severity | Treatment Delay | Randomised Trials | Individual Patient Data | Patients Alteplase
      KOL-Index: 21450

      BACKGROUND: In ROCKET AF, rivaroxaban was non-inferior to adjusted-dose warfarin in preventing stroke or systemic embolism among patients with atrial fibrillation (AF). We aimed to investigate whether the efficacy and safety of rivaroxaban compared with warfarin is consistent among the subgroups of patients with and without previous stroke or transient ischaemic attack (TIA).

      METHODS: In ROCKET AF, patients with AF who were at increased risk of stroke were randomly assigned (1:1) in a ...

      Known for Previous Stroke | Warfarin Patients | Atrial Fibrillation | Transient Ischaemic Attack | Rocket Rivaroxaban
      KOL-Index: 18820

      BACKGROUND: Patients with minor acute ischemic stroke or transient ischemic attack are at high risk for subsequent stroke, and more potent antiplatelet therapy in the acute setting is needed. However, the potential benefit of more intense antiplatelet therapy must be assessed in relation to the risk for major bleeding. The SOCRATES trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes) was the first trial with ticagrelor in patients with ...

      Known for Transient Ischemic Attack | Acute Stroke | Ticagrelor Aspirin | Major Bleeding | Antiplatelet Therapy
      KOL-Index: 18251

      BACKGROUND: The treatment of ischaemic stroke with neuroprotective drugs has been unsuccessful, and whether these compounds can be used to reduce disability after recurrent stroke is unknown. The putative neuroprotective effects of antiplatelet compounds and the angiotensin II receptor antagonist telmisartan were investigated in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial.

      METHODS: Patients who had had an ischaemic stroke were randomly assigned in a two ...

      Known for Recurrent Stroke | Prevention Regimen | Dipyridamole Versus | Patients Telmisartan | Cognitive Function
      KOL-Index: 17668

      BACKGROUND: In 2015, five randomised trials showed efficacy of endovascular thrombectomy over standard medical care in patients with acute ischaemic stroke caused by occlusion of arteries of the proximal anterior circulation. In this meta-analysis we, the trial investigators, aimed to pool individual patient data from these trials to address remaining questions about whether the therapy is efficacious across the diverse populations included.

      METHODS: We formed the HERMES collaboration to ...

      Known for Endovascular Thrombectomy | Individual Patient Data | Randomised Trials | Reduced Disability | Ischaemic Stroke
      KOL-Index: 17620

      IMPORTANCE: Endovascular thrombectomy with second-generation devices is beneficial for patients with ischemic stroke due to intracranial large-vessel occlusions. Delineation of the association of treatment time with outcomes would help to guide implementation.

      OBJECTIVE: To characterize the period in which endovascular thrombectomy is associated with benefit, and the extent to which treatment delay is related to functional outcomes, mortality, and symptomatic intracranial ...

      Known for Endovascular Thrombectomy | Medical Therapy | 3 Months | Ard 95 | Symptom Onset
      KOL-Index: 17523

      BACKGROUND: Systolic blood pressure of more than 185 mm Hg is a contraindication to thrombolytic treatment with intravenous alteplase in patients with acute ischaemic stroke, but the target systolic blood pressure for optimal outcome is uncertain. We assessed intensive blood pressure lowering compared with guideline-recommended blood pressure lowering in patients treated with alteplase for acute ischaemic stroke.

      METHODS: We did an international, partial-factorial, open-label, ...

      Known for Acute Ischaemic Stroke | Blood Pressure | Intravenous Alteplase | Functional Status | Intracranial Haemorrhage
      KOL-Index: 16307

      BACKGROUND: Randomised trials have shown that alteplase improves the odds of a good outcome when delivered within 4·5 h of acute ischaemic stroke. However, alteplase also increases the risk of intracerebral haemorrhage; we aimed to determine the proportional and absolute effects of alteplase on the risks of intracerebral haemorrhage, mortality, and functional impairment in different types of patients.

      METHODS: We used individual patient data from the Stroke Thrombolysis Trialists' (STT) ...

      Known for Intracerebral Haemorrhage | Acute Ischaemic Stroke | Patients Alteplase | Individual Patient Data | Secondary Analysis
      KOL-Index: 16219

      CONTEXT: Recurrent stroke prevention guidelines suggest that larger reductions in systolic blood pressure (SBP) are positively associated with a greater reduction in the risk of recurrent stroke and define an SBP level of less than 120 mm Hg as normal. However, the association of SBP maintained at such levels with risk of vascular events after a recent ischemic stroke is unclear.

      OBJECTIVE: To assess the association of maintaining low-normal vs high-normal SBP levels with risk of ...

      Known for Systolic Blood Pressure | Sbp Mm Hg | Recurrent Stroke | 95 Patients | Low Normal
      KOL-Index: 15833

      The use of perfusion imaging to guide selection of patients for stroke thrombolysis remains controversial because of lack of supportive phase three clinical trial evidence. We aimed to measure the outcomes for patients treated with intravenous recombinant tissue plasminogen activator (rtPA) at a comprehensive stroke care facility where perfusion computed tomography was routinely used for thrombolysis eligibility decision assistance. Our overall hypothesis was that patients with 'target' ...

      Known for Computed Tomography | Target Mismatch | Stroke Thrombolysis | Treatment Decision | Primary Analysis
      KOL-Index: 15790

      BACKGROUND: Whether intravenous tissue plasminogen activator (alteplase) is effective beyond 3 h after onset of acute ischaemic stroke is unclear. We aimed to test whether alteplase given 3-6 h after stroke onset promotes reperfusion and attenuates infarct growth in patients who have a mismatch in perfusion-weighted MRI (PWI) and diffusion-weighted MRI (DWI).

      METHODS: We prospectively and randomly assigned 101 patients to receive alteplase or placebo 3-6 h after onset of ischaemic ...

      Known for Alteplase Placebo | Patients Mismatch | Reperfusion Infarct Growth | Thrombolytic Evaluation | Pwi Dwi
      KOL-Index: 15421

      BACKGROUND: Evidence regarding whether imaging can be used effectively to select patients for endovascular thrombectomy (EVT) is scarce. We aimed to investigate the association between baseline imaging features and safety and efficacy of EVT in acute ischaemic stroke caused by anterior large-vessel occlusion.

      METHODS: In this meta-analysis of individual patient-level data, the HERMES collaboration identified in PubMed seven randomised trials in endovascular stroke that compared EVT with ...

      Known for Evt Patients | Endovascular Stroke | Mortality 90 | Baseline Imaging | Symptomatic Intracranial
      KOL-Index: 15138

      BACKGROUND: Prolonged lowering of blood pressure after a stroke reduces the risk of recurrent stroke. In addition, inhibition of the renin-angiotensin system in high-risk patients reduces the rate of subsequent cardiovascular events, including stroke. However, the effect of lowering of blood pressure with a renin-angiotensin system inhibitor soon after a stroke has not been clearly established. We evaluated the effects of therapy with an angiotensin-receptor blocker, telmisartan, ...

      Known for Recurrent Stroke | Cardiovascular Events | Telmisartan Placebo | Hazard Ratio | Blood Pressure
      KOL-Index: 15107

      BACKGROUND: Cryptogenic strokes constitute 20 to 30% of ischemic strokes, and most cryptogenic strokes are considered to be embolic and of undetermined source. An earlier randomized trial showed that rivaroxaban is no more effective than aspirin in preventing recurrent stroke after a presumed embolic stroke from an undetermined source. Whether dabigatran would be effective in preventing recurrent strokes after this type of stroke was unclear.

      METHODS: We conducted a multicenter, ...

      Known for Embolic Stroke | Dabigatran Aspirin | Major Bleeding | Hazard Ratio | Undetermined Source
      KOL-Index: 14921

      BACKGROUND: Trials of endovascular therapy for ischemic stroke have produced variable results. We conducted this study to test whether more advanced imaging selection, recently developed devices, and earlier intervention improve outcomes.

      METHODS: We randomly assigned patients with ischemic stroke who were receiving 0.9 mg of alteplase per kilogram of body weight less than 4.5 hours after the onset of ischemic stroke either to undergo endovascular thrombectomy with the Solitaire FR (Flow ...

      Known for Ischemic Stroke | Endovascular Therapy | Alteplase Patients | Imaging Selection | Internal Carotid

      Key People For Ischemic Stroke

      Top KOLs in the world
      Ralph L Sacco
      ischemic stroke northern manhattan study carotid plaque
      Harold P Jr Adams
      ischemic stroke cerebral infarction subarachnoid hemorrhage
      José Biller
      ischemic stroke cerebral infarction neurologic complications
      Laurens Jaap Kappelle
      ischemic stroke type 2 diabetes cognitive impairment
      Geoffrey Alan Donnan
      ischemic stroke atrial fibrillation intracerebral haemorrhage
      Jeffrey L Saver
      acute ischemic stroke endovascular thrombectomy united states

      Geoffrey Alan Donnan:Expert Impact

      Concepts for whichGeoffrey Alan Donnanhas direct influence:Ischemic stroke,  Acute stroke,  Atrial fibrillation,  Ischaemic stroke,  Stroke patients,  Acute ischemic stroke,  Intracerebral haemorrhage,  3 months.

      Geoffrey Alan Donnan:KOL impact

      Concepts related to the work of other authors for whichfor which Geoffrey Alan Donnan has influence:Ischemic stroke,  Mechanical thrombectomy,  Intravenous thrombolysis,  Endovascular treatment,  Atrial fibrillation,  Blood pressure,  Cerebral ischemia.



      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Andrei V. Alexandrov, is Professor and Chairman, Department of Neurology, College of Medicine, University of Tennessee Health Sciences Center, Memphis, TN (ORCID: https://orcid.org/0000-0001-8871-1023). | The Melbourne Brain Centre, Royal Melbourne H

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.